Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, is using lentiviral vector delivery platforms to develop and commercialize therapies, initially targeting skin, connective tissue and metabolic diseases. Our scientists utilize ex vivo and in vivo technologies to switch gene targets and create optimal therapies for a multitude of genetic diseases.
 |
 |
 |